Consuelo Egla Diana Rabinovich, MD

Professor of Pediatrics
Campus mail:
2301 Erwin Road, Chc T0909, Durham, NC 27710
Phone:
(919) 684-6575
Email address:
rabin001@mc.duke.edu
Therapeutic agents for treatment of Juvenile Arthritis.
Pediatric inflammatory eye disease (uveitis).
Pediatric localized scleroderma.
Education and Training
- Fellow, Pediatric Rheumatology, Pediatrics, Duke University, 1988 - 1991
- Resident, Pediatrics, Duke University, 1985 - 1988
- M.D., Southern Illinois University, 1985
Selected Grants and Awards
- New CARRA Registry
- A Multicenter, Open-Label Trial of Intravenous Golimumab, a Human Anti-TNF¿ Antibody, in Pediatric Subjects With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy
- A randomized, double-blind, placebo-controlled, multicenter, phase 3 efficacy and safety study of 2 dose levels of subcutaneious anakinra in patients with Still's disease
- An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 1 to 17 Years, with Systemic Juvenile Idiopathic Arthritis (sJIA), Followed by an Extensi
- An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 2 to 17 Years, with Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) Followed b
- Long-Term Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Tocilizumab in Patients with Polyarticular-Course adn Systemic Juvenile Idiopathic Arthritis
- Training Program in Inflammatory and Immunological Diseases
- Enhancing Clinical Meaningfulness and Usefulness of PROMIS Pediatric Measures Via Validation in Children and Adolescents with Rheumatic Disease, Cancer of Inflammatory Bowel Disease
- WA28118: Tocilizumab in Systemic JIA
- CARRA Registry Continuation
- IDENTIFICATION OF VUR GENES BY COMBINED LINKAGE ANALYSIS AND EXOME SEQUENCING
- WA28117: Tocilizumab in Polyarticular-Course JIA